From the Research
Ryzodeg (insulin degludec/insulin aspart) is recommended for adults with diabetes mellitus as a once or twice daily injection with main meals, with a typical starting dose of 10 units once daily for insulin-naïve type 2 diabetes patients. The dosage and administration of Ryzodeg should be individualized based on the patient's needs, with dose adjustments made according to blood glucose measurements, and increases or decreases of 2-4 units at a time 1.
Key Considerations
- The insulin degludec component provides basal coverage for approximately 24 hours, while the insulin aspart component covers mealtime glucose excursions 2.
- Ryzodeg should be administered subcutaneously in the abdomen, upper arm, or thigh, and injection sites should be rotated within the same region to reduce the risk of lipodystrophy 3.
- Blood glucose monitoring is essential when initiating or adjusting Ryzodeg therapy, and patients should be aware of hypoglycemia risks, especially when changing insulin regimens 4.
- The efficacy and safety of Ryzodeg have been demonstrated in clinical trials, including a phase 3, randomized, open-label, treat-to-target non-inferiority trial in patients with type 1 diabetes 5.
Administration and Dosage
- The typical starting dose for insulin-naïve type 2 diabetes patients is 10 units once daily with the main meal.
- Patients switching from other insulin regimens should start with the same total daily insulin dose.
- For type 1 diabetes, Ryzodeg should be used in combination with mealtime insulin for other meals, with dosing based on individual needs.
- Dose adjustments should be made based on blood glucose measurements, with increases or decreases of 2-4 units at a time.